This does not however exclude the chance that in specific cases it may be essential for the MHRA to require additional data from the generic applicant. Businesses whose applications have been invalidated or refused based on the previous policy have entitlement to re-send their applications. The MHRA shall assess those applications in accordance with the revised policy. The MHRA has written to trade associations and additional guidance on the useful implications will be published in future problems of ‘MAIL’, the MHRA updating service for medications. Specific enquiries should be addressed to the most common MHRA Licensing Division administration contact points.. Change of plan concerning generic product approvals Following a latest judgment of the European Court of Justice in the ‘Novartis’ case , the MHRA has made a decision to change its plan concerning the evaluation of generic equivalents of line extension items.The combination is believed by The researchers could be better at fighting the disease than any drug cocktail currently used. The group say the treatment stopped the developing breasts tumours in their tracks and the cancers remained at bay even after treatment had completed. Related StoriesNew findings reveal association between colorectal tumor and melanoma medication treatmentNew RNA test of blood platelets can be used to detect location of cancerMeat-rich diet plan may increase kidney tumor riskThe promising results have led to a scientific trial which is currently under way involving 3,000 women and the total email address details are due in half a year.